/
Oncology
Adenocarcinoma
95
Pipeline Programs↗
92
Active Trials↗
56
Companies Involved↗
Adenocarcinoma is a moderately active landscape with 95 programs across 56 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Corcept Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd.. 23 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 16
Phase 253
Phase 323
Approved
No programs
Analysis
Modality Breakdown
79%
Small molecule
72 of 91 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 91 classified programs, each share of the total. Modality classified for 99% of 95 pipeline programs.
Analysis
Trial Status
297
clinical trials
Completed106 · 36%
Recruiting44 · 15%
Unknown status44 · 15%
Terminated36 · 12%
Not yet recruiting26 · 9%
Active, not recruiting20 · 7%
Other21 · 7%
Clinical Trials
Trial Activity
297 trials
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Recruiting·—·Phase 2·NCT05729646·90 enrolled
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)